Pharma penny stock under Rs 50 bags new order worth USD 27,540 from Taha Drugs & Chemicals Co. Ltd
DSIJ Intelligence-1 / 16 Dec 2025/ Categories: Penny Stocks, Trending
The shares of the company have an ROE of 19 per cent and an ROCE of 25 per cent.
On Tuesday, shares of Shelter Pharma Ltd plunged 1.55 per cent to Rs 36.15 per share from its previous closing of Rs 36.70 per share. The stock’s 52-week high is Rs 69.70 per share and its 52-week low is Rs 35.70 per share. The stock falls under the S&P BSE SME IPO with a lot size of 3,000 shares.
Shelter Pharma Limited has successfully secured a significant international order from Taha Drugs & Chemicals Co., Ltd. in Sudan. The contract is for the supply of D3 Cure Capsules 3*10, a fixed-cost order with a total value of USD 27,540. The significant terms require the order to be executed within a relatively short two-month time period.
About the Company
Shelter Pharma Limited is a prominent pharmaceutical and nutraceutical company renowned for its dedication to research, innovation and quality. Established to provide accessible and effective healthcare solutions, the company has consistently delivered products that meet the highest industry standards. Their state-of-the-art facilities, world-class team of experts and commitment to ethical practices have earned them a reputation of trust in the industry. Shelter Pharma's mission is to promote well-being and health through innovative, high-quality nutraceuticals.
Shelter, a trusted name in herbal remedies for six decades, has seamlessly blended traditional healing principles with modern, aggressive research and state-of-the-art technology since its founding in 1965. Continuing its commitment to natural healthcare, Shelter has expanded its Nutraceutical portfolio with the launch of D3 Cure Capsules, targeting the rapidly growing international market to prevent and treat Vitamin D deficiency. This new science-backed solution supports bone health (aiding calcium absorption), boosts the immune system, enhances mood, and contributes to muscle and cardiovascular function, reinforcing Shelter's strategic focus on high-quality wellness and preventive healthcare to drive sustained growth.
The company has a market cap of over Rs 40 crore. The company’s current debt is Rs 1.22 crore, which is 3 per cent of the market cap. The promoters own 47.19 per cent while the general public owns the rest, with 52.82 per cent as of November 2025. There are 1,093 shareholders as of June 2025. The shares of the company have an ROE of 19 per cent and an ROCE of 25 per cent. The stock is up 1.26 per cent from its 52-week low of Rs 35.70 per share.
Disclaimer: The article is for informational purposes only and not investment advice.